Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 69Terminated 27Active not recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Breast Neoplasms 116Carcinoma, Non-Small-Cell Lung 68Multiple Myeloma 56Prostatic Neoplasms 55Lymphoma 40Neoplasm Metastasis 38Leukemia, Lymphocytic, Chronic, B-Cell 35Melanoma 32Leukemia, Myeloid, Acute 32Neoplasms 31Ovarian Neoplasms 30Lymphoma, Non-Hodgkin 27Lung Neoplasms 26Hematologic Neoplasms 25Triple Negative Breast Neoplasms 24Glioblastoma 22Myelodysplastic Syndromes 20Fallopian Tube Neoplasms 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Hodgkin Disease 19Sarcoma 18Carcinoma, Renal Cell 18Squamous Cell Carcinoma of Head and Neck 16Small Cell Lung Carcinoma 16Glioma 16Urinary Bladder Neoplasms 15Colorectal Neoplasms 15Lymphoma, Mantle-Cell 14Leukemia 14Head and Neck Neoplasms 14

Interventions

pembrolizumab 1lenvatinib 1avelumab 1Radiosurgery 1Nivolumab 1Ipilimumab 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Has results × Skin Neoplasms × Clear all
NCT03944941 2026-06-02

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
60 enrolled 19 charts
Dermatologic

Skin Neoplasms

NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
26 enrolled 9 charts
Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT03071406 2026-03-11

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
50 enrolled 12 charts
Dermatologic

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡